University of michigan medical school curriculum vitae
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL CURRICULUM VITAE Departments of Neurology & Radiology PERSONAL DATA
Home Address: 106 Woodshire Drive, Pittsburgh, PA 15215
Business Address: UPMC, Kaufmann Building,
Suite 811, 3471 Fifth Avenue, Pittsburgh PA 15213.
Dates Attended Name and Location Degree Received and Major Subject Of Institution 1973-1979
GRADUATE: Dates Attended Name and Location Degree Received and Major Subject Of Institution 1979-1987 1983-1984
Programme de License, Faculté de Philosophie
Dates Attended Name and Location Program Director and Discipline Of Institution 1987-1991
Section of Clinical Epidemiology Rochester, MN
Advanced Fellowship in Neurology (Movement Disorders)
Years Inclusive Name and Location of Institution Rank/Title
ACADEMIC ADMINISTRATIVE APPOINTMENTS Years Inclusive Name and Location of Institution
Director Parkinson's disease clinic, VA Medical Center
R&D Committee, Alternate Chairperson,
Years Inclusive Name and Location of Institution Title Or Position 1998-Present SCIENTIFIC ACTIVITIES
International reviewer for New Zealand Neurological Society
Member brain imaging council, Society of Nuclear Medicine
Session Coordinator, Movement Disorders, Society of Nuclear
Department of Veterans Affairs, Scientific reviewer.
Grant reviewer, Michael J. Fox Foundation
Grant reviewer, MRC (Medical Research Council), United Kingdom.
Ad hoc journal reviewer: Annals of Neurology, Archives of Neurology, Brain, Cleveland Clinic
Journal of Medicine, Journal of Neurology, Journal of Nuclear Medicine, Neurobiology of Aging, Pharmacopsychiatry, Progress in Neurobiology.
Investigator-initiated research (PI only): 1a. Scaife Family Foundation; Seed Grant; Project: Acetylcholinesterase and Glucose PET Imaging in Parkinsonism and Dementia Period: 2/99-2/00; $25,000. 1b. VA Competitive Pilot Study; Seed Grant; Project: Acetylcholinesterase and Glucose PET Imaging in Parkinsonism and Dementia Period: 4/99-4/00; $48,000. 1c. VA MERIT REVIEW Project: Acetylcholinesterase and Glucose PET Imaging in Parkinsonism and Dementia (25%): 7/00-7/03; $312,600. 2. Intra-mural; Title: 99mTc-ECD brain spect normal database project. Period 1/00-4/04; $75,000. 3. Samuel and EmmaWinters Foundation; Seed Grant; Project: Cardiovascular dysautonomia in parkinsonism and dementia; 9/99-9/01; $5,000. 4a. Veteran Research Foundation of Pittsburgh; Seed Grant; Project: Striatal D2 receptors and amantadine treatment in parkinsonism and dementia; 1/00-1/01; $10,000. 4b. The Pittsburgh Foundation; Project: Striatal D2 receptors and amantadine in Parkinson's disease with neurobehavioral symptoms; 7/00-7/02; $150,000. 5. NIA (5P50 AG05133 18): Therapeutic correlates of AChE PET imaging in AD; 6/00-6/05; $416,500. 6. Scaife Family Foundation; Seed Grant; Effects of unilateral instrastriatal dopaminergic grafts in MPTP-treated hemiparkinsonian monkeys; 10/00-10/01; $25,000. 7. NIH (P01 NS019608; (project part of program project Dr. Zigmond): PET, Posturographic and Clinical Markers of Early PD. 5/03-4/08; $1,025,000. 8. VA MERIT REHAB REVIEW (E3270R): Neurobiological and Postural Control Mechanisms Underlying Risk of Falling; 4/04-3/07; $771,500. 9. NIA: Executive, Postural Control and Cholinergic Functions in WMD; project part of Dr. Studenski's Pepper Program application; 12/04-11/06; $60,000
10. NIA (: 1 P30 AG024827-01); Imaging core; Pittsburgh Older American's Independence Center; PI: Stephanie Studenski, MD, MPH 9/04-8/09; $100,000.
Industry-sponsored studies (PI only): 1. Mylan Pharmaceuticals: An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease.; 9/00-present; $50,000. 2. Parexel Int: A Phase II, Randomized, Double-Blind, Active-Controlled Study to Determine the Optimal Initial Titration Regime of Ropinirole CR Tablets in Parkinson’s Disease Patients Not Receiving Other Dopaminergic Therapies; 9/01-6/03; $40,000. 3. Parexel Int: A Long-Term, Open-Label Continuation Study of Once Daily Administration of
Ropinirole CR Tablets to Patients with Parkinson’s Disease Who Completed the Previous Phase 2 Ropinirole CR Trial - 167; 3/02-present; $40,000. 4. Boehringer Ingelheim: A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE). Protocol # 1198.100; 9/03-present; $150,000. 5. A 12-week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy; 7/04-7/05; $140,000.
CERTIFICATION AND LICENSURE
SPECIALTY CERTIFICATION Certifying
American Board or Psychiatry and Neurology (# 44021)
American Board of Nuclear Medicine (#06414)
MEDICAL OR OTHER PROFESSIONAL LICENSURE:
HONORS AND AWARDS
(European Science Foundation) 'Biological markers of psychiatric and neurological illness'. Lucca, Italy. Mayo Clinic, Department of Neurology Research Award
Invited for the Senior Vice-Chancellor Research Seminar
(An Imaging Perspective on the Cholinergic Hypothesis in Dementia) Induction of member to ANA
MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES Organization
Dutch Society of Clinical Neurochemistry
Sigma Xi, The Scientific Research Society (Mayo Foundation Chapter)
American Academy of Neurology (# 019909)
American Society of Nuclear Medicine (#201951)
Medical students 1/83-6/83:
Tutor of first year medical students. University of Nijmegen, the Netherlands.
Supervisor research assignments medical students, University of Limburg,
Teacher of block ‘Head Injury’, Neurology, Medical School;
Proctor for medical students; Mayo Medical School.
1998-present: Teacher in Neuroscience course, Medical students MS-II,
1998-present: Teacher in Clinical Skills Course, Medical Students MS-II,
Teacher Clinical Neurology course, Neurology residents
Teacher Nuclear Medicine rounds, Radiology residents
Teacher in Neuroscience course, Post-Graduate Students,
2000-present: Teacher in Neuroscience course, Medical students MS-II,
2000-present: Teacher in Clinical Skills Course, Medical Students MS-II,
2000-present: Teacher in Clinical Neuroscience Clerkship, Medical Students MS-III-IV,
Teacher in Clinical Neuroscience Integrated Life Sciences Course; Medical
Teacher in Disabilities Medicine Course; Medical Students I-II, University of
Teacher in Master of Occupational Therapy (MOT) program, Parkinson's disease
School of Health and Rehabilitation Sciences, University of Pittsburgh
Longitudinal clerkship MD/PhD program University of Pittsburgh: 5-6/2000: Sara
Neurology resident special elective movement disorders: 12/2001:
Pediatric neurology resident elective movement disorders: 3/2004:
Neurology fellow: 2003-2004:
Eric Farbman, MD, movement disorders fellow, University of
Pittsburgh & VA movement disorders clinics.
Neurosurgery fellow: 1-4/2001:
Geriatric medicine fellows St Margaret Hospital: 1/2002:
Post-graduate Neuroscience students externship:
Neurology resident research mentors: 2/2002: Uma COMMITTEE AND ADMINISTRATIVE SERVICE
Member Scientific Review Committee, Department of
Member Residency Recruitment Committee, Department of
Department of Veteran Affairs; Special Positron Emission
Department of Veteran Affairs; PET/CT scan advisory group
Review consultant VA MERIT program, Subcommittee for Mental Health and Behavioral Sciences, Department of Veterans Affairs, Washington, DC.
Report Q205 Exhaustion of IPRs in cases of recycling and repair of goods Questions Analysis of the current statutory and case laws In your country, is exhaustion of IPRs provided either in statutory law or under case law with respect to patents, designs and trademarks? Exhaustion of IPRs is provided in statutory law for patents, designs and trademarks. What legal provisions are appl
Überörtliche Berufs-ausübungsgemeinschaft Bei über 90% der oft wässrigen Durchfäl e kommt es nach zwei bis maximal sechs Tagen spontan zur Ausheilung. Für die Meisten ist somit eine überbrückende, den Flüssigkeits- und Elektrolytverlust ausgleichende Therap ie ausreichend. Die ausreichende Zufuhr von Flüssigkeit und Elektrolyten stel t die aller wichtigste Maßnahme dar und m